DE69731756D1 - Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung - Google Patents

Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung

Info

Publication number
DE69731756D1
DE69731756D1 DE69731756T DE69731756T DE69731756D1 DE 69731756 D1 DE69731756 D1 DE 69731756D1 DE 69731756 T DE69731756 T DE 69731756T DE 69731756 T DE69731756 T DE 69731756T DE 69731756 D1 DE69731756 D1 DE 69731756D1
Authority
DE
Germany
Prior art keywords
melanoma
cell line
melanomantic
immundominant
melanom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69731756T
Other languages
English (en)
Other versions
DE69731756T2 (de
Inventor
M Pardoll
M Jaffee
Adam Adler
L Topalian
A Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
US Department of Health and Human Services
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69731756D1 publication Critical patent/DE69731756D1/de
Publication of DE69731756T2 publication Critical patent/DE69731756T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69731756T 1996-08-16 1997-08-04 Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung Expired - Lifetime DE69731756T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2409896P 1996-08-16 1996-08-16
US24098P 1996-08-16
PCT/US1997/012868 WO1998006746A2 (en) 1996-08-16 1997-08-04 Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same

Publications (2)

Publication Number Publication Date
DE69731756D1 true DE69731756D1 (de) 2004-12-30
DE69731756T2 DE69731756T2 (de) 2005-12-15

Family

ID=21818860

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69731756T Expired - Lifetime DE69731756T2 (de) 1996-08-16 1997-08-04 Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung

Country Status (8)

Country Link
US (1) US6187306B1 (de)
EP (1) EP0929318B1 (de)
JP (5) JP2001517206A (de)
AT (1) ATE283069T1 (de)
AU (1) AU3889997A (de)
CA (1) CA2263503C (de)
DE (1) DE69731756T2 (de)
WO (1) WO1998006746A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1069917A4 (de) * 1998-03-20 2005-02-09 Genzyme Corp Neue komplementierende rezeptor-liganden paare und adoptive immunotherapie die diese verwendet
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
WO2001098464A2 (en) * 2000-06-22 2001-12-27 Aventis Pasteur Limited Continuous adherent melanocyte cell line
CN1756568A (zh) 2002-10-09 2006-04-05 衣阿华中央卫生系统 使用表达α(1,3)－半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
GB2424070B (en) * 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
SI1889059T1 (sl) 2005-05-27 2009-12-31 Oncimmune Ltd Izboljšani imunotestni postopek
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US8574848B2 (en) * 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
CN102666663A (zh) * 2009-10-23 2012-09-12 道康宁东丽株式会社 新的有机聚硅氧烷共聚物
JP7409773B2 (ja) 2015-07-31 2024-01-09 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 改変された細胞および治療の方法
EP4338799A3 (de) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumorinfiltrierende lymphozyten und therapieverfahren
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595653A (en) 1981-06-09 1986-06-17 Lee Biomolecular Research Laboratories, Inc. Process for assaying cellular immunity
US5045320A (en) 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE69114299T3 (de) 1990-09-14 2005-09-15 The Johns Hopkins University Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
EP1216710B1 (de) * 1991-10-04 2006-04-05 Whitehead Institute For Biomedical Research Regulierung der systemischen Immunantworten mittels Zytokinen und Antigenen
ES2224113T5 (es) * 1994-02-16 2009-05-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Polipeptido antigenico asociado al melanoma, epitopos del mismo y vacunas contra melanoma.
CA2188432C (en) * 1994-04-22 2011-02-01 Yutaka Kawakami Melanoma antigens
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Also Published As

Publication number Publication date
WO1998006746A2 (en) 1998-02-19
WO1998006746A3 (en) 1998-05-07
CA2263503C (en) 2012-04-10
ATE283069T1 (de) 2004-12-15
US6187306B1 (en) 2001-02-13
EP0929318A2 (de) 1999-07-21
AU3889997A (en) 1998-03-06
DE69731756T2 (de) 2005-12-15
JP2016106137A (ja) 2016-06-16
CA2263503A1 (en) 1998-02-19
JP2012001548A (ja) 2012-01-05
EP0929318B1 (de) 2004-11-24
JP2008044969A (ja) 2008-02-28
JP2001517206A (ja) 2001-10-02
JP2014012738A (ja) 2014-01-23

Similar Documents

Publication Publication Date Title
DE69731756D1 (de) Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung
DE69737592D1 (de) Mittel gegen juckreiz
ATE247986T1 (de) Vorrichtung und verfahren zur aufnahme eines medizinischen instrumentes
IT8119641A0 (it) Apparato e metodo per la determinazione ottica di giochi meccanici.
IT7920944A0 (it) Metodo, apparato e corpo disupporto di registrazioni per la registrazione ottica di informazioni.
DE69205396D1 (de) Geschäftsformularsätze und Verfahren und Vorrichtung zu deren Herstellung.
RU93048636A (ru) 7-/замещенные/-8-/замещенные/-9-/замещенные амино/-6-диметил-6-дезокситетрациклины, промежуточные соединения, способы получения соединений, способ профилактики и лечения и фармацевтическая композиция
DE69232537T2 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
DE69332744T2 (de) Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
HUP9801702A2 (hu) Diszpergálható szemcsés rendszer fogak érzékenységének csökkentésére
DE69109213T2 (de) Verfahren und Vorrichtung zur Erzeugung von Röntgenstrahlen.
DE3781989T2 (de) Vorrichtung und verfahren zur informationskodierung eines optischen strahles.
FI881877A (fi) 17 -(cyklopropylamino) androst-5 -en-3 -ol och naerstaoende foereningar, som aer anvaendbara som c17-20-lyas-inhibitorer.
DK0734461T3 (da) Anvendelse af et apparat til dannelse af exciteret gas
DK0786004T3 (da) Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
ATE181549T1 (de) Verfahren zur herstellung von (s)-3-amino-1- substituiert-pirrolidine
DE69022485D1 (de) Elektro-Schweissmuffe sowie Verfahren und Vorrichtung zu deren Herstellung.
ATE200658T1 (de) Zeolithe und verfahren zu deren herstellung
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
DE69001050T2 (de) Verfahren um oktanbedarfserhoehungsreglerzusaetze zur erzeugen.
DE69132575T2 (de) Sampangin-derivate zur verwendung als antimykotische und antimykobakterielle wirkstoffe
DE59008436D1 (de) Ionenstrahlgerät sowie Verfahren zur Durchführung von Potentialmessungen mittels eines Ionenstrahles.
DE69100835T2 (de) Apparat zur Erzeugung von Röntgenstrahlen und Verfahren zur Isolierung des Apparatus zur Erzeugung von Röntgenstrahlen.
DE69111728T2 (de) Verfahren und Gerät zur Erzeugung von elektrophotographischen Bildern.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition